01 — At a Glance
The Pharmaceutical Comedian Nobody Asked For
Q3 FY26 Snapshot (Consolidated) — Revenue ₹425 cr (-9.8% YoY), PAT ₹44 cr (-40.5% YoY), EPS ₹4.83 (~₹19.3 annualized). But wait—there’s ₹49 cr of goods sitting in “transit” that management “forgot” to book. Whoops.
- Q3 Revenue₹425 Cr
- Q3 PAT₹44 Cr
- Q3 EPS₹4.83
- Annualised EPS (Q3×4)₹19.32
- EBITDA Margin Q324.2%
- Book Value₹249
- Price to Book2.54x
- Debt / Equity0.32x
- Dividend Yield0.78%
- 52-Week High/Low₹972 / ₹557
The Real Story: Aarti Pharmalabs is that student in class who had a stellar science project, then accidentally dropped it an hour before presentation. Q3 revenue fell 10% YoY because management shipped ₹49 cr of goods on DAP (Delivered at Place) incoterms—meaning the accountant didn’t recognize revenue until delivery, not shipment. If those goods had been booked, topline would be +11% instead of -10%. Context is your friend.
02 — Introduction
The Pharmaceutical Company That Discovered Chaos Science
Aarti Pharmalabs Limited is born from the 2022 demerger of Aarti Industries’ pharma vertical—India’s only global leader in caffeine derivatives (15-20% world market share), and a CDMO/CMO shop serving 21 global customers. Think of them as the guy who solved the world’s coffee supply chain, then got distracted building a new factory that fell three months behind schedule.
The company operates three segments: (1) Xanthine Derivatives (caffeine, theophylline, aminophylline) at 49% of revenue; (2) APIs & Intermediates at 39%; and (3) CDMO/CMO services at 12%. Global reach of 56% international sales. Six plants. Three R&D centres. Capacity of nearly 15,000 MTPA across all products by FY27. Sounds solid on paper. The execution? Let’s just say Atali plant is the cautionary tale of Q3.
CY25 revenue was ₹2,115 cr (up 14% YoY). FY25 PAT ₹272 cr (up 25% YoY). Stock delivered 32% CAGR over 3 years. Then Q3 FY26 arrived and said: “Nope, not today.”
Concall Honesty (Feb 2026): Management admitted Atali had “newer staff and newer nature of plant” leading to “validation complexity.” Translation: we hired freshers and they broke things. At least they said it out loud.
03 — Business Model: They Make Caffeine. Not Jokes.
Three Boring Segments That Pay Real Cash
Xanthine Derivatives: India’s largest caffeine capacity. Used 65% in beverages (energy drinks, sodas), 35% in pharma/nutraceuticals. Current utilization ~500 MT/month at the “mother site”; new expansion adds 300 MT/month (mechanical completion March 2026). Expected ramp by Q1 FY27. Pricing just got interesting: China dropped export rebates on caffeine (~13% support removal), which could lift prices 8-10% over time. Management: “pricing has bottomed out.” US tariffs on Chinese caffeine are 20%, while India gets duty-free. This is their moment.
APIs & Intermediates: The problem child. Oncology, corticosteroids, CVD, anti-cancer drugs. 52% to regulated markets, 34% to rest of world, 14% non-regulated. Growth disappointment in FY26 because partners “slowed down in taking up quantities.” Translation: we expected them to buy more, they didn’t. Margin pressure from generic pricing that “only goes down,” never up. Recovery depends on launches (Apixaban, new oncology APIs) and capacity debottlenecking. Management target: return to ₹200 cr quarterly API run-rate by FY27. Not there yet.
CDMO/CMO Services: The dark horse. 21 customers, 59 active projects (40 commercial, 19 in development), but ~80% of revenue from 7-8 projects. Single-digit million dollar POs per project. Some programs with 60-70% wallet share. This is concentration risk masquerading as scale. Management says they’ll meet FY26 guidance but exceeding it “now looks difficult” due to Atali delays and incoterms shipping delays.
Xanthine Revenue %49%₹~180 Cr/Qtr
API Revenue %39%₹~140 Cr/Qtr
CDMO Revenue %12%₹~43 Cr/Qtr
💬 Real talk: If management says pricing has bottomed, why is the stock still down 13.8% YTD? Drop your view in comments.
04 — Financials Overview: Q3 FY26
The Numbers Nobody Wants to Discuss
